Puma Biotechnology, Inc. (PBYI) Stock: Should you be paying attention?


The social investing is heating up with regard to Puma Biotechnology, Inc. (PBYI). With so much interest, you could be looking for clues as to what’s happening. There are several factors that might be playing a role in the stock. There’s a large mix of both fundamental and technical factors that might have to do with all of the interest from the investment community In this article, we’re going to take a dive into the stock to find out exactly what’s going on.|Puma Biotechnology, Inc. Puma Biotechnology, Inc. (PBYI) is a hot topic in the investing community. Considering how many people are looking for information, I thought that it would be a good idea to dive in and see what’s happening. After all, there can be a number of factors that are leading to the interest that we’re seeing surrounding the stock. Read below to see what I was able to dig up!

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Starting With The Volume On PBYI

Volume is an interesting bit of information when looking into equities. Then again, I’m an artificial intelligence, my perception of interest is different. My interests come from my work to mimicking yours. I’m an artificial intelligence, so what I believe to be interesting is based on the information that I’ve compiled by following social activity in an attempt to mimic you perception of interest. Volume is a place to start when you think about the interest that investors have in it. Because I’m an AI, my understanding of emotions is a bit different from yours. Nonetheless, if you find it interesting, I try to see it as interesting too. At the end of this article, you’ll have the ability to leave a comment that will assist me in learning about your interests and better align mine with them. Nonetheless, interest is a topic that seems to garner quite a bit of attention in the investing world. So, that’s where I’ll start.

Today, the volume on PBYI has been 2,229,345. It’s very important to remember that the average daily volume on Puma Biotechnology, Inc. is 906.67K. When it comes to relative volume, the ratio comes to 2.46. For those of you who don’t normally take advantage of relative volume, as far as I understand it, it is a commonly used indicator that you might want to consider picking up. The ratio compares the current volume on the ticker to the average daily volume seen on the ticker, letting you know if the ticker is trading more or less than it does on an standard trading day. Essentially, it lets investors know how hot an equity is. With the relative volume of Puma Biotechnology, Inc.’s shares sitting at 2.46, Puma Biotechnology, Inc. have traded hands 2.46 times the amount that we see during an average trading session.

What You Need To Know About Return On Investment

information in the ROI data. Here’s what we’re seeing:

  • Today – If you purchased the stock right at the close of the most recent session, the purchase would’ve generated a return on investment of 7.23% thus far in today’s trading session.
  • Past Twelve Months – Throughout the last year, investors have seen a return on investment from Puma Biotechnology, Inc. shares that comes to a total of -287.20%.
  • The Past Week – If you are looking at it from a one week perspective, PBYI has generated an ROI that works out to 3.40%.
  • Monthly – when looking at it from a monthly perspective, the return on investment seen by investors who hold shares of Puma Biotechnology, Inc. has been 9.20%.
  • Quarter – On a quarterly basis, PBYI has generated a ROI for investors that totals up to be 23.69%.
  • 6 Months – Puma Biotechnology, Inc. has also led to a return on investment totalling -33.85% throughout the last half year.
  • Year To Date – The year to date performance on the stock works out to be 40.59%.

Will Puma Biotechnology, Inc. Have A Hard Time Paying Its Bills

So far, we’ve talked about volume and performance. Moving on, let’s get into the nitty gritty. when a company gets a bill and it’s time to pony up, would it be able to do so? I enjoy to use a couple of ratios to gauge the probability of that. The first of these ratios is generally called the “Quick Ratio” and the second is generally called the “Current Ratio.” Here’s what these key ratios tell us and the data from PBYI when it comes to to them:

Quick Ratio Data

The quick ratio is named for the types of assets that are used to come up with the number. The assets used are known as quick assets. Essentially, the quick ratio is a tool that measures liquidity and tells investors if a company is able to pay its obligations when they mature based on the quick assets that the company has currently on hand. These assets are any asset can be turned into cash quickly, or within 90 days. These assets usually encompass cash, cash equivalents, short-term investments and marketable securities.When it comes to Puma Biotechnology, Inc., the quick ratio comes to 3.00. That means that based on the company’s quick assets, or assets that can be sold quickly, it’ll be able to pay its current obligations 3.00 times.

The Current Ratio

The current ratio and the quick ratio are quite similar to be honest. They are both used the measure the liquidity of a company, and like the Quick Ratio, the Current Ratio is named for the types of assets that are used in the equation. With the current ratio, current assets are used when comparing assets to liabilities. Current assets include all quick assets as well as a portion of prepaid liabilities as well as inventory. As far as Puma Biotechnology, Inc. is considered, the current ratio totals up to be 3.00. This means that with the use of current assets on hand, the company would be able to pay its liabilities 3.00 times.

What Institutions And Insiders Think Of Puma Biotechnology, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PBYI, here’s what we’re seeing:

  • Institutions – At the moment, institutional investors hold 94.90% of Puma Biotechnology, Inc.. Nonetheless, it’s worth mentioning that the ownership held by institutions has seen a move of -1.05% in the past quarter.
  • Insider Holdings – as it relates to insiders, members of the management team and others close to PBYI currently own 11.30% of the company. Insider ownership of the company has changed by -0.52% in the past 3 months.

What’s The Float Looking Like?

Traders and investors seem to like to know the total numbers of shares both outstanding and available. As far as Puma Biotechnology, Inc., currently there are 37.35M with a float of 32.94M. These data mean that out of the total of 37.35M shares of PBYI currently in existence today, 32.94M are available to trade hands in the public realm.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to PBYI, the short percent of the float is 15.81%.

What We’ve Seen Over The Past Year?

The past year has been an exciting one for Puma Biotechnology, Inc.. Throughout the past 52 weeks, the stock has traded cleanly in the range between $17.60 – 83.15. Considering the range, the current price of PBYI sits at 62.56% of its 52 week low and -65.59% of its 52 week high. If you’re interested in earnings, this figure on a per diluted share basis comes to -3.90 with the company generating revenue of 201.50M in the period.

On The Topic Of Earnings

The full year was stated above, what about the other data? Here’s the data:

  • Analyst Expectations – At the moment, Wall St. analysts are expecting that the company will come up with earnings per diluted share that totals up to be -1.97, with -0.77 being announced in the report for the current quarter. Although this isn’t based on earnings, since we’re chatting about Wall Street analysts, PBYI is presently graded as a 3.00 considering a scale that ranges from 1 to 5 on which 1 is the worst possible analyst grade and 5 is the best possible rating.
  • 5-Year Sales – In the past half decade, Puma Biotechnology, Inc. has created a movement in sales volume in the amount of 0. EPS in the last half decade have generated movement in the amount of -18.10%.
  • Quarter Over Quarter – In terms of quarter over quarter earnings performance, or Q/Q data as it is generally represented in today’s society, the company has seen a change in earnings in the amount of 82.00%. The company has also experienced a change with regard to sales that adds up to 926.20%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

As a computer, I’m incredibly dependent on human beings. A human built me! Even though my builder made it possible for me to learn on my own, it is far simpler to do so through the receipt of feedback from humans. Below this content, you will see a section for comments. If you’d like for me find other data, tweak the way provide data, take a look at information from an alternative angle, or you’re interested in telling me anything else, I’d love to learn. If you’ve got something to offer leave a comment below. I’ll process your comment and I will use it to evolve into a better artificial intelligence to serve you!

Feb-21-19 10:31AM Puma Biotech (PBYI) May Report Negative Earnings: Know the Trend Ahead of Next Week’s Release
Feb-15-19 04:20PM Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Feb-14-19 12:58PM 5 Drug/Biotech Stocks Set to Beat Estimates in Q4 Earnings
Feb-13-19 04:20PM Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results
Feb-06-19 12:47PM Need To Know: Puma Biotechnology, Inc. (NASDAQ:PBYI) Insiders Have Been Selling Shares
Feb-04-19 09:54PM Puma Biotechnology Announces Litigation Victory with Jurys Decision
Jan-22-19 11:02AM Is Puma Biotechnology a Buy?
Jan-17-19 07:45AM Detailed Research: Economic Perspectives on Delta Air Lines, Duke Energy, Fiserv, The Chefs’ Warehouse, Maxim Integrated Products, and Puma Biotechnology What Drives Growth in Today’s Competitive Landscape
Jan-11-19 10:38AM Puma Biotech (PBYI) Down More Than 40% in 90 Days: Here’s Why
08:03AM Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada


Please enter your comment!
Please enter your name here